Drugs / INETAGUGENE GEPERPAVEC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04047732 | Aug 2019 → Oct 2022 | autosomal recessive congenital ichthyosis 1 | Krystal Biotech, Inc. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05735158 | Mar 2023 → Mar 2024 | autosomal recessive congenital ichthyosis | Krystal Biotech, Inc. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INETAGUGENE GEPERPAVEC | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650243 ↗ |
| Known as | HSV1-TGM1 | “HSV1-TGM1 vector (KB105)” NCT04047732 ↗ |
| Known as | KB105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04047732 ↗ |
| Route | Topical | “topically administered KB105” NCT04047732 ↗ |
| Target | TGM1 | “expressing human transglutaminase 1 (TGM1)” NCT04047732 ↗ |